This study therefore examined these three molecular pharmacological properties (affinity, duration of binding and efficacy) for 35 β‐blockers for the human β2 and β1‐AR, ranked compounds for each property, and compared the overall properties with those of propranolol to determine which would theoretically have the best overall molecular pharmacological profile as a potential anti‐cancer β‐blocker. This evidence concerns the gene ADRB1 and cancer.